Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2015 09:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Receives FDA Orphan Drug Designation for Vasomera (PB1046) for the Treatment of Cardiomyopathy Associated With Dystrophinopathies

MALVERN, Pa., Dec. 1, 2015 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developing...
November 09, 2015 09:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Initiation of Phase 2a Multiple Ascending Dose Study of Once-Weekly Basal Insulin PE0139 in Type 2 Diabetes

MALVERN, Pa., Nov. 9, 2015 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs focused on developing...
September 03, 2015 09:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio to Present at Rodman & Renshaw 17th Annual Global Investment Conference

MALVERN, Pa., Sept. 3, 2015 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs focused on developing...
June 07, 2015 08:30 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals Announces Positive Data for Type 2 Diabetes Treatments PE0139 and PB1023

PE0139 was well tolerated; pharmacokinetic / pharmacodynamic profile supports once-weekly dosing PE0139 demonstrated synergistic action with weekly GLP-1 receptor agonist PB1023 MALVERN,...
June 01, 2015 08:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals to Present at the American Diabetes Association 75th Scientific Sessions

MALVERN, Pa., June 1, 2015 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs focused on developing...
April 22, 2015 07:30 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Promising Pre-Clinical Results for PB1046 in Models of Duchenne Muscular Dystrophy

Chronic PB1046 treatment shown to ameliorate Duchenne muscular dystrophy myopathies, slow cardiac deterioration in mice Compound protected skeletal muscle, decreased fibrosis Data to be...
March 12, 2015 07:30 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Raises $40 Million Series C Financing Led by AstraZeneca

Proceeds to enable advancement of lead drug candidates – once-weekly basal insulin and once-weekly Vasoactive Intestinal Peptide MALVERN, Pa., March 12, 2015 (GLOBE NEWSWIRE) -- PhaseBio...
March 03, 2015 09:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Expansion of Leadership Team

Clay Thorp named Executive Chairman of the board Jonathan P. Mow becomes Chief Executive Officer Dr. James Ballance appointed Vice President, Research and Scientific Affairs MALVERN,...